1. Nakano S, Abe Y, Nakajima K, Sano S, Yamamoto O, Wakamatsu K, Ito S, Hayashi M, Suzuki T：Establishment of a mouse model for post-inflammatory hyperpigmentation.
Pigment Cell Melanoma Res, 34(1):101-110, 2021
2. Shibata Y, Okamoto T, Saruta T, Matsuoka F, Fujieda M, Sano S：De novo novel splice-site mutation in FLT4/VEGFR3 is associated with Milroy disease.
J Dermatol, 48(1):e26-e28, 2021
3. Ishimoto T, Takaishi M, Ishizuka M, Inoue K, Sano S：Photodynamic therapy selectively eradicates ultraviolet B-induced squamous cell carcinoma lesion through rapid apoptosis to restore normal epidermis in a mouse model.
J Dermatol, 48(2)：245-247, 2021
4. Nakajima K, Nakajima R, Morisaka H, Nakajima H, Sano S：Beneficial Impact of Apremilast on Palmoplantar Keratodermas.
Acta Derm Venereol, 101(4)：adv00437, 2021
5. Imafuku S, Nakagawa H, Igarashi A, Morita A, Okubo Y, Sano S, Tada Y, Nemoto O, Rozzo SJ, Kawamura M, Ohtsuki M：Long-term efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 5-year extension of a phase 3 study (reSURFACE 1).
J Dermatol,〔Online ahead of print〕2021
6. Nakajima H, Nakajima K, Takaishi M, Ohko K, Serada S, Fujimoto M, Naka T, Sano S：The Skin-Liver Axis Modulates the Psoriasiform Phenotype and Involves Leucine-Rich α-2 Glycoprotein.
J Immunol, 206(7)：1469-1477, 2021
7. Shibata Y, Sano S：Keratosis pilaris caused by dupilumab for the treatment of bronchial asthma.
8. Shibata Y, Nakajima H, Nakajima K, Serada S, Fujimoto M, Naka T,Sano S：Leucine-rich α-2 glycoprotein is a predictive marker of therapeutic efficacy of the biologics in psoriatic arthritis.
9. Teraishi M, Oguro T, Kusume E, Kobashi H, Sano H, Fujioka A, Yamamoto M, Nakajima H , Sano S：Pralatrexate for refractory mycosis fungoides in two Japanese patients.
J Dermatol,48(5)：667-671，2021
10. Hashida Y, Higuchi T, Nakajima S, Nakajima K, Ujihara T, Kabashima K, Sano S, Daibata M：Human Polyomavirus 6 Detected in Cases of Eosinophilic Pustular Folliculitis.
J Infect Dis, 223(10)：1724-1732，2021
11. Umezawa Y, Asahina A, Imafuku S, Tada Y, Sano S, Morita A, Sakurai S, Hoshii N, Tilt N, Nakagawa H：Efficacy and Safety of Certolizumab Pegol in Japanese Patients with Moderate to Severe Plaque Psoriasis:52-Week Results.
Dermatol Ther (Heidelb),11(3)：943-960，2021
12. Igarashi A, Nakagawa H, Morita A, Okubo Y, Sano S, Imafuku S, Tada Y, Honma M, Mendelsohn AM, Kawamura M, Ohtsuki M：Efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 64-week phase 3 study (reSURFACE 1).
J Dermatol, 48(6)：853-863, 2021
13. Nakajima K, Yamamato M, Ohsawa R, Nakajima H,Maeda N , Muro Y, Sano S：Anti-MJ/NXP-2 antibodies-positive adult-onset dermatomyositis with lichen mixe dematosus and endometrial carcinoma.
14. Muro Y, Yamano Y, Yoshida K, Oto Y, Nakajima K, Mitsuma T, Kikuchi S, Matsumae A, Ogawa-Momohara M, Takeichi T, Kondoh Y, Katayama M, Todoroki Y, Tanaka Y, Satoh M, Akiyama M：Immune recognition of lysyl-tRNA synthetase and isoleucyl-tRNA synthetase by anti-OJ antibody-positive sera.
J Autoimmun 122：102680.2021
15. Ohsawa R, Sano H, Ikeda M, Sano S：Clinical and histopathological views of morbilliform rash after COVID-19 mRNA vaccination mimic those in SARS-CoV-2 virus infection-associated cutaneous manifestations.
J Dermatol Sci 103(2)：124-127. 2021
16. Morisaka H, Nakajima R, Aoyama Y, Teraishi M, Nakajima H, Ogawa M, Sano S：Case of pigmented skin metastasis of breast carcinoma.
J Dermatol 48(9)：e476-e477. 2021
17. Nakajima H, Nakajima K, Serada S, Fujimoto M, Naka T, Sano S：The involvement of leucine-rich α-2 glycoprotein in the progression of skin and lung fibrosis in bleomycin-induced systemic sclerosis model.
Mod Rheumatol 31(6)：1120-1128. 2021
18. Yamamoto M, Nakajima H, Aoyama Y, Teraishi M, Nakajima K, Sano S：The diagnostic utility of Elastica van Gieson stain in hydrophilic polymer embolism.
J Dermatol 48(11)：e538-e540. 2021
19. Aoki N, Saruta Y, Tanaka S, Nakajima R, Sano H, Sano S：Skin ulcer at the injection site of BNT162b2 mRNA COVID-19 vaccine.
